Securities class action allegations cast shadow over regeneron pharmaceuticals (regn)– hagens berman

San francisco, jan. 27, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) faces a securities fraud class action after shares of the company plunged $84.59 on oct. 31, 2024, wiping out about $9 billion of market value. hagens berman has opened an investigation into whether regeneron may have misled investors about its marketing and reimbursement practices related to its eylea® product, an injection to treat age-related macular degeneration by inhibiting anti vascular endothelial growth factor (“anti-vegf”), and urges investors who purchased regeneron shares and suffered substantial losses to submit your losses now.
REGN Ratings Summary
REGN Quant Ranking